Alto Neuroscience Statistics
Total Valuation
ANRO has a market cap or net worth of $86.03 million. The enterprise value is -$80.18 million.
Important Dates
The next estimated earnings date is Friday, March 7, 2025, before market open.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ANRO has 26.97 million shares outstanding. The number of shares has increased by 408.92% in one year.
| Current Share Class | 26.97M |
| Shares Outstanding | 26.97M |
| Shares Change (YoY) | +408.92% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 8.27% |
| Owned by Institutions (%) | 60.88% |
| Float | 19.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.09, with a Debt / Equity ratio of 0.09.
| Current Ratio | 13.09 |
| Quick Ratio | 12.96 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.33 |
Financial Efficiency
Return on equity (ROE) is -56.72% and return on invested capital (ROIC) is -34.75%.
| Return on Equity (ROE) | -56.72% |
| Return on Assets (ROA) | -32.36% |
| Return on Invested Capital (ROIC) | -34.75% |
| Return on Capital Employed (ROCE) | -35.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$857,418 |
| Employee Count | 67 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -76.46% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 8.92 |
| Relative Strength Index (RSI) | 35.89 |
| Average Volume (20 Days) | 238,395 |
Short Selling Information
The latest short interest is 4.05 million, so 15.01% of the outstanding shares have been sold short.
| Short Interest | 4.05M |
| Short Previous Month | 3.97M |
| Short % of Shares Out | 15.01% |
| Short % of Float | 20.87% |
| Short Ratio (days to cover) | 18.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -63.38M |
| Pretax Income | n/a |
| Net Income | -57.45M |
| EBITDA | -62.93M |
| EBIT | -63.38M |
| Earnings Per Share (EPS) | -$3.05 |
Full Income StatementBalance Sheet
The company has $181.70 million in cash and $15.49 million in debt, giving a net cash position of $166.21 million or $6.16 per share.
| Cash & Cash Equivalents | 181.70M |
| Total Debt | 15.49M |
| Net Cash | 166.21M |
| Net Cash Per Share | $6.16 |
| Equity (Book Value) | 165.05M |
| Book Value Per Share | 6.12 |
| Working Capital | 169.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$45.93 million and capital expenditures -$1.92 million, giving a free cash flow of -$47.85 million.
| Operating Cash Flow | -45.93M |
| Capital Expenditures | -1.92M |
| Free Cash Flow | -47.85M |
| FCF Per Share | -$1.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |